Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Natixis Advisors L.P.

Natixis Advisors L.P. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 15.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 279,620 shares of the biopharmaceutical company’s stock after purchasing an additional 36,711 shares during the period. Natixis Advisors L.P.’s holdings in Gilead Sciences were worth $22,652,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of GILD. Commonwealth Equity Services LLC raised its holdings in shares of Gilead Sciences by 12.9% in the fourth quarter. Commonwealth Equity Services LLC now owns 372,452 shares of the biopharmaceutical company’s stock worth $30,172,000 after acquiring an additional 42,554 shares during the last quarter. Robertson Stephens Wealth Management LLC grew its holdings in shares of Gilead Sciences by 32.4% during the fourth quarter. Robertson Stephens Wealth Management LLC now owns 5,349 shares of the biopharmaceutical company’s stock worth $433,000 after buying an additional 1,310 shares in the last quarter. McIlrath & Eck LLC raised its position in shares of Gilead Sciences by 67.2% in the fourth quarter. McIlrath & Eck LLC now owns 550 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 221 shares during the last quarter. First Trust Direct Indexing L.P. grew its stake in Gilead Sciences by 23.0% in the 4th quarter. First Trust Direct Indexing L.P. now owns 30,157 shares of the biopharmaceutical company’s stock worth $2,443,000 after acquiring an additional 5,648 shares during the period. Finally, Searle & CO. purchased a new position in shares of Gilead Sciences during the 4th quarter worth about $328,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of several analyst reports. Maxim Group dropped their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and lowered their price objective for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Wells Fargo & Company cut their target price on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research report on Monday, March 4th. Morgan Stanley dropped their price target on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a research note on Friday, April 26th. Finally, StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, April 27th. Eleven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $83.69.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $64.78 on Monday. The business has a 50 day simple moving average of $70.55 and a 200 day simple moving average of $75.78. The company has a debt-to-equity ratio of 1.08, a current ratio of 0.98 and a quick ratio of 0.72. The firm has a market capitalization of $80.66 billion, a price-to-earnings ratio of 179.94, a price-to-earnings-growth ratio of 1.31 and a beta of 0.22. Gilead Sciences, Inc. has a 12-month low of $64.33 and a 12-month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. The firm had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. Gilead Sciences’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the company earned $1.37 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 3.74 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.75%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.29% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.